Neurocrine Biosciences
NBIX
218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.
13% more capital invested
Capital invested by funds: $3.27B → $3.68B (+$417M)
3% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 37
0.51% more ownership
Funds ownership: 97.13% → 97.64% (+0.51%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less funds holding
Funds holding: 225 → 218 (-7)
10% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 80
39% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $20.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$214M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.4M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$85.8M |
| 4 |
Goldman Sachs
New York
|
+$42.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$80M |
| 2 |
O
OrbiMed
New York
|
-$72.3M |
| 3 |
Millennium Management
New York
|
-$51.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.4M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$26.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBHC
251
Brown Brothers Harriman & Co
New York
| – | -$4K | -92 | Closed |
|
252
EARNEST Partners
Atlanta,
Georgia
| – | -$1K | -28 | Closed |
|
|
OFW
253
Omnia Family Wealth
Aventura,
Florida
| – | -$1K | -23 | Closed |
|
|
WTB
254
Washington Trust Bank
Spokane,
Washington
| – | -$1K | -13 | Closed |
|
|
WAM
255
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| – | +$386 | +9 | New |
|
NBIX Hedge Fund Activity: Q1 2017 in Review
218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.
The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.
- 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
- Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
- 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
- The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
- The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.
Based on aggregated 13F filings for Q1 2017.